Arcturus Therapeutics (ARCT) Reports Q4 Loss of $1.03

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.03). Revenue for the quarter came in at $7.2 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Citi reiterates Buy rating on AMD with $575 price target post TMT conference
• Accountability Research Downgrades salesforce.com (CRM) to Hold